Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Accumulated Expenses: 2015-2024

Historic Accumulated Expenses for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $10.7 million.

  • Seres Therapeutics' Accumulated Expenses fell 63.98% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 63.98%. This contributed to the annual value of $10.7 million for FY2024, which is 52.38% down from last year.
  • Per Seres Therapeutics' latest filing, its Accumulated Expenses stood at $10.7 million for FY2024, which was down 52.38% from $22.5 million recorded in FY2023.
  • Over the past 5 years, Seres Therapeutics' Accumulated Expenses peaked at $59.8 million during FY2022, and registered a low of $10.7 million during FY2024.
  • Over the past 3 years, Seres Therapeutics' median Accumulated Expenses value was $22.5 million (recorded in 2023), while the average stood at $31.0 million.
  • As far as peak fluctuations go, Seres Therapeutics' Accumulated Expenses skyrocketed by 216.98% in 2021, and later tumbled by 62.38% in 2023.
  • Over the past 5 years, Seres Therapeutics' Accumulated Expenses (Yearly) stood at $14.2 million in 2020, then soared by 216.98% to $45.1 million in 2021, then spiked by 32.70% to $59.8 million in 2022, then crashed by 62.38% to $22.5 million in 2023, then slumped by 52.38% to $10.7 million in 2024.